<DOC>
	<DOCNO>NCT00578669</DOCNO>
	<brief_summary>The primary purpose study determine whether , among smoker elevate depressive symptom , sequential antidepressant pharmacotherapy fluoxetine ( 20 mg ) begin 8 week prior extend throughout standard smoke cessation treatment transdermal nicotine patch ( ST-TNP ) result superior short-and long-term smoking cessation outcome compare sequential pharmacotherapy placebo medication combine ST-TNP . The secondary aim study test hypothesis , among smoker elevate depressive symptom , sequential treatment fluoxetine result low level depressive symptom negative mood high level positive mood immediately prior throughout course smoke cessation treatment relative placebo condition .</brief_summary>
	<brief_title>Sequential Use Fluoxetine Smokers With Elevated Depressive Symptoms</brief_title>
	<detailed_description>Cigarette smoke lead cause death disability United States , account 430,000 death country every year . The selection hypothesis smoke prevalence argue smoker unable quit successfully likely posse risk factor characteristic make difficult quit , nicotine dependence psychiatric comorbidity . As , significant stride help `` today 's '' smoker quit ultimately find ability develop specialized treatment target particular need subgroups smoker , especially high risk relapse . Depression psychiatric disorder frequently associate cigarette smoking adult strong association demonstrate cigarette smoking depressive disorder depressive symptom . In fact , prospective analysis National Health Nutrition Examination Survey show smoker elevate depressive symptom 40 % le likely nondepressed smoker quit nine year later . The development efficacious , specialized treatment nicotine dependence smoker elevate depressive symptom would address need provide physician effective treatment alternative large number smoker depressive symptom see daily clinical practice . This study examine hypothesis smoker elevate depressive symptom treat fluoxetine 8 week prior quit extend throughout 8 week standard treatment nicotine patch post-quit demonstrate superior cessation outcome compare placebo medication combine standard treatment nicotine patch , administer identical treatment schedule . A secondary hypothesis examine whether reduction depressive symptom negative mood increase positive mood great sequential fluoxetine versus placebo condition .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>Regular smoker least one year Currently smoke least 10 cigarette per day Elevated depressive symptom Uses tobacco product Current Axis I disorder , include Major Depressive Disorder Psychoactive substance abuse dependence ( exclude nicotine dependence ) within past year Current use psychotropic medication Use antidepressant medication within past 6 month Current suicidal risk History significant medical illness , cardiovascular disease , neurological , gastrointestinal , systemic illness Pregnancy breast feeding Use nicotine replacement therapy medication smoke cessation provide researcher quit attempt</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Smoking Cessation</keyword>
	<keyword>Tobacco Use Cessation</keyword>
	<keyword>Antidepressants</keyword>
</DOC>